Traders Buy High Volume of Biogen Put Options (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) was the target of some unusual options trading activity on Wednesday. Stock traders bought 5,799 put options on the stock. This is an increase of 230% compared to the average daily volume of 1,759 put options.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently made changes to their positions in the business. Bell Investment Advisors Inc bought a new stake in Biogen in the second quarter worth $27,000. Align Financial LLC grew its position in Biogen by 339.3% during the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 95 shares during the last quarter. Canton Hathaway LLC purchased a new position in shares of Biogen in the third quarter worth $31,000. Ashurst Perkins Coie Trust Co boosted its holdings in Biogen by 92.2% in the third quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 83 shares during the last quarter. Finally, Balance Wealth Partners LLC purchased a new stake in shares of Biogen during the 3rd quarter valued at about $39,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

NASDAQ:BIIB traded down $4.91 during mid-day trading on Wednesday, reaching $247.82. The stock had a trading volume of 925,900 shares, compared to its average volume of 1,208,653. Biogen has a 12 month low of $138.00 and a 12 month high of $258.78. The stock has a 50-day simple moving average of $225.10 and a two-hundred day simple moving average of $200.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. The stock has a market capitalization of $36.62 billion, a PE ratio of 43.95, a P/E/G ratio of 2.99 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.63 billion. During the same period in the previous year, the business posted $4.81 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, equities analysts anticipate that Biogen will post 12.29 earnings per share for the current year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted earnings of $2.62 per share, well above the $1.99–$2.06 analyst estimates, while revenue rose 10.6% year over year to $2.80 billion, exceeding expectations. Biogen earnings report
• Positive Sentiment: Growth Portfolio revenue increased 49% to $1.26 billion, supported by newer medicines and the first full-quarter contribution from products acquired through Apellis. Rare-disease revenue also climbed 27% to $676 million. Biogen Q3 revenue report
• Positive Sentiment: Management raised the low end of its full-year 2026 reported non-GAAP EPS outlook to $12.20–$13.00, reinforcing the view that newer products are offsetting pressure on Biogen’s established multiple sclerosis franchise. Biogen raises guidance
• Neutral Sentiment: Barclays raised its price target from $200 to $230 but maintained an “equal weight” rating. The new target remains below the recent trading level, indicating limited upside in the bank’s view. Barclays Biogen rating
• Negative Sentiment: Biogen posted a $20.6 million GAAP loss, or $0.14 per share, versus a profit in the prior-year quarter, primarily because of acquisition-related research and development charges. Investors also purchased 5,799 put options, about 230% of average daily volume, signaling increased near-term hedging or bearish speculation. Biogen GAAP loss report

Wall Street Analyst Weigh In

BIIB has been the subject of several recent analyst reports. Stifel Nicolaus set a $242.00 price objective on shares of Biogen in a report on Thursday, September 10th. BMO Capital Markets reissued a “market perform” rating and set a $220.00 price objective on shares of Biogen in a report on Monday, October 12th. Oppenheimer reiterated an “outperform” rating and issued a $300.00 target price on shares of Biogen in a research note on Wednesday, July 29th. Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and lifted their price objective for the company from $190.00 to $235.00 in a research report on Monday, July 13th. Finally, Mizuho increased their price objective on shares of Biogen from $221.00 to $241.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $242.96.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.